Stocktoria
BIOLIFE SOLUTIONS INC BLFS
BIOLIFE SOLUTIONS INC (BLFS) earns a Piotroski F-score of 6/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $96.2M at a -4.8% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.33 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 6/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.28 |
| Retained earnings / assets | -0.837 |
| EBIT / assets | -0.041 |
| Equity / liabilities | 10.939 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| BLFS | BIOLIFE SOLUTIONS INC | 6/9 | 10.32 | — | +28.9% |
| VASO | VASO Corp | 6/9 | 0.72 | 21.3 | +2.7% |
| CBLL | Ceribell, Inc. | 3/9 | 3.97 | — | +36.1% |
| OM | Outset Medical, Inc. | 6/9 | -9.87 | — | +5.1% |
| FOCL | EDAP TMS SA | 3/9 | -5.4 | — | +1.6% |
| ELMD | Electromed, Inc. | 6/9 | 10.99 | 46.4 | +17% |
| IRIX | IRIDEX CORP | 4/9 | -8.01 | — | +8.2% |
About BIOLIFE SOLUTIONS INC
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction products, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; CryoCase cryo-compatible transparent rigid containers for closed-system fill and retrieval, and automated cell processing machines; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
FAQ
Is BLFS financially healthy?
BIOLIFE SOLUTIONS INC's Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does BLFS pay a dividend?
No, BIOLIFE SOLUTIONS INC does not currently pay a dividend.
How profitable is BLFS?
In FY2025, BIOLIFE SOLUTIONS INC had a net margin of -4.8% and a return on equity of -1.2%.
What is the analyst price target for BLFS?
The average Wall-Street price target for BIOLIFE SOLUTIONS INC is $32.11, about 8.2% below the recent price, from 9 analysts (consensus: strong buy).
Is BLFS a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on BIOLIFE SOLUTIONS INC: a Piotroski F-score of 6/9, an Altman Z″ in the safe zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.